Zacks Upgrades Achillion Pharmaceuticals to “Outperform” (ACHN)
Achillion Pharmaceuticals (NASDAQ:ACHN) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research report issued on Wednesday, AmericanBankingNews.com reports. The firm currently has a $3.60 price target on the stock. Zacks‘ price target points to a potential upside of 8.47% from the company’s current price.
In other Achillion Pharmaceuticals news, major shareholder Qvt Associates Gp Llc sold 170,239 shares of the stock on the open market in a transaction dated Monday, December 30th. The shares were sold at an average price of $3.34, for a total transaction of $568,598.26. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Achillion Pharmaceuticals (NASDAQ:ACHN) traded up 1.81% on Wednesday, hitting $3.319. 1,438,193 shares of the company’s stock traded hands. Achillion Pharmaceuticals has a 52-week low of $2.26 and a 52-week high of $10.17. The stock’s 50-day moving average is $3.12 and its 200-day moving average is $5.1. The company’s market cap is $320.9 million.
Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.06. During the same quarter in the previous year, the company posted ($0.20) earnings per share.
Separately, analysts at Credit Suisse downgraded shares of Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, October 16th. They now have a $4.00 price target on the stock, down previously from $11.00. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and one has assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $5.57.
Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.